Abstract
The accumulation of misfolded or unfolded proteins in endoplasmic reticulum (ER) lumen results in the activation of an adaptive stress process called the unfolded protein response (UPR). As the most conserved signaling branch of the UPR, Inositol-requiring enzyme 1 (IRE1) possesses both Ser/Thr kinase and RNase activities operating as major stress sensors, mediating both adaptive and pro-apoptotic pathways under ER stress. Over the last three decades, a mounting body of evidence has shown that IRE1 signaling dysfunction is involved in the pathology of various neurological disorders. Targeting this pathway has emerged as a promising therapeutic strategy against these diseases. In this review, we provide a general overview about the expression and physiological function of IRE1 signaling and its pathophysiological roles in the central nervous system diseases.
Keywords: Inositol-requiring enzyme 1, X box-binding protein 1, diseases, central nervous system, Alzheimer`s disease, Parkinson`s disease, ischemic stroke.
Current Neuropharmacology
Title:The Role of IRE1 Signaling in the Central Nervous System Diseases
Volume: 16 Issue: 9
Author(s): Haibo Ni, Qin Rui, Di Li*, Rong Gao and Gang Chen
Affiliation:
- Department of Translational Medicine Center, The First People`s Hospital of Zhangjiagang City, Suzhou, Jiangsu,China
Keywords: Inositol-requiring enzyme 1, X box-binding protein 1, diseases, central nervous system, Alzheimer`s disease, Parkinson`s disease, ischemic stroke.
Abstract: The accumulation of misfolded or unfolded proteins in endoplasmic reticulum (ER) lumen results in the activation of an adaptive stress process called the unfolded protein response (UPR). As the most conserved signaling branch of the UPR, Inositol-requiring enzyme 1 (IRE1) possesses both Ser/Thr kinase and RNase activities operating as major stress sensors, mediating both adaptive and pro-apoptotic pathways under ER stress. Over the last three decades, a mounting body of evidence has shown that IRE1 signaling dysfunction is involved in the pathology of various neurological disorders. Targeting this pathway has emerged as a promising therapeutic strategy against these diseases. In this review, we provide a general overview about the expression and physiological function of IRE1 signaling and its pathophysiological roles in the central nervous system diseases.
Export Options
About this article
Cite this article as:
Ni Haibo , Rui Qin , Li Di *, Gao Rong and Chen Gang, The Role of IRE1 Signaling in the Central Nervous System Diseases, Current Neuropharmacology 2018; 16 (9) . https://dx.doi.org/10.2174/1570159X16666180416094646
DOI https://dx.doi.org/10.2174/1570159X16666180416094646 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spontaneous Coronary Artery Dissection: Does Being Unemployed Matter? Insights from the GSCAD Registry
Current Cardiology Reviews Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Potential Role of Hydrogen Sulfide in the Pathogenesis of Vascular Dysfunction in Septic Shock
Current Vascular Pharmacology The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Current Drug Targets Invited Editorial: Malaria by <i>Plasmodium knowlesi</i>, A Zoonosis Transmitted by Vectors
Recent Patents on Anti-Infective Drug Discovery Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design Antimicrobial Resistance in the 21st Century: A Multifaceted Challenge
Protein & Peptide Letters Platinum Sensor for Quantifying Caffeine in Drug Formulations
Current Pharmaceutical Analysis Why Methylene Blue Have to Be Always Present in the Stocking of Emergency Antidotes
Current Drug Targets Anti-Vascular Endothelial Growth Factor Treatment in Retinal Vein Occlusions
Current Drug Therapy N-acetylcysteine Exerts Protective Effects and Prevents Lung Redox Imbalance and Peroxynitrite Generation in Endotoxemic Rats
Medicinal Chemistry Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets Hypopituitarism in the Elderly: Multifaceted Clinical and Biochemical Presentation
Current Aging Science